The core challenge in AML therapy lies in the cancer cells’ capacity to evade programmed cell death, or apoptosis, a process that is tightly regulated by a family of proteins known as BCL-2. In normal physiology, BCL-2 family proteins orchestrate the intrinsic apoptotic pathway, balancing pro-apoptotic and anti-apoptotic signals to maintain cellular homeostasis. Leukemic cells subvert this system by overexpressing pro-survival BCL-2 proteins, thereby evading chemotherapy-induced apoptosis and perpetuating malignancy. BH3 mimetics act by simulating the BH3 domain—a critical pro-apoptotic motif—enabling these compounds to selectively inhibit anti-apoptotic BCL-2 family proteins and restore apoptosis in malignant cells.

Among BH3 mimetics, venetoclax has emerged as the most clinically successful agent. This selective BCL-2 inhibitor has demonstrated remarkable efficacy in clinical trials, especially when combined with hypomethylating agents or low-dose cytarabine. These combinations have been shown to significantly enhance remission rates and prolong survival in AML patients, particularly in older individuals or those unfit for intensive chemotherapy—a patient population historically lacking viable therapeutic options. The US Food and Drug Administration (FDA) has accordingly approved these regimens, marking a pivotal advancement in AML management.

Assistant Professor Alan Prem Kumar, a leading voice in pharmacology at NUS Medicine, co-led the review alongside Assistant Professor Courtney DiNardo from the University of Texas MD Anderson Cancer Center. Reflecting on the clinical impact, Asst Prof Kumar emphasizes that venetoclax has “transformed the treatment landscape” by providing first-time access to effective therapy for frail AML patients. This breakthrough represents a paradigm shift away from the traditional, often intolerable chemotherapy regimens towards more targeted, tolerable interventions.

The review, published in Nature Reviews Clinical Oncology, synthesizes findings from over a thousand peer-reviewed articles, with a detailed focus on 236 rigorously selected studies. This exhaustive assessment maps the molecular underpinnings of BH3 mimetic function, elucidates mechanisms of drug resistance, evaluates clinical outcomes, and explores technological advances such as BH3 profiling and mitochondrial profiling. These profiling techniques allow for precise identification of the apoptotic dependencies of individual AML cells, enabling clinicians to predict drug sensitivity and tailor therapies accordingly.

Crucially, BH3 mimetics have demonstrated the ability not only to target proliferating leukemic cells but also to eradicate quiescent, non-dividing populations harboring complex genetic aberrations. This capability is significant as these dormant cells often contribute to relapse and disease persistence. However, while venetoclax heralds an era of improved outcomes, resistance remains a formidable obstacle. AML cells frequently adapt by shifting survival reliance to alternate anti-apoptotic proteins such as MCL-1 or BCL-xL, or by acquiring mutations in adverse prognostic genes including TP53, KRAS, and FLT3.

Donavan Jia Jie Tan, a first-year medical student and study co-author, underscores this therapeutic challenge, noting that cancer cells’ adaptability forces continuous innovation in treatment strategies. By integrating multiple targeted agents, combination regimens, or advanced drug delivery technologies that concurrently disrupt diverse anti-apoptotic pathways, researchers hope to mitigate resistance and enhance the durability of remissions.

This personalized treatment approach is further bolstered by the advent of BH3 and mitochondrial profiling, which Dr Lam Hiu Yan highlights as powerful tools for aligning therapeutic strategy with tumour biology. These methods facilitate the identification of patients most likely to benefit from venetoclax versus those who may require alternative BH3 mimetics targeting MCL-1 or BCL-xL, thus refining clinical decision-making and minimizing unwarranted toxicity.

Looking ahead, Asst Prof Kumar posits that the future of AML therapy hinges on the precision personalization of treatment regimens. Moving beyond a one-size-fits-all paradigm, tailoring interventions to the molecular and cellular characteristics of each patient’s leukemia will optimize efficacy and improve quality of life. This bespoke therapeutic model signals a shift towards more intelligent, biology-driven oncology care.

Independent expert Professor Chng Wee Joo of NUS Medicine, unaffiliated with the study, affirms the transformative impact of venetoclax-based therapies, especially in older adults and medically complex patients. He highlights the dramatic improvements in remission and survival that would have been unimaginable merely a decade ago. Prof Chng identifies next steps in research aimed at enhancing treatment precision, broadening accessibility, and ultimately converting AML from a once invariably fatal disease to a manageable chronic condition.

Current clinical trials are actively examining venetoclax in combination with groundbreaking agents including FLT3 inhibitors and CD47-targeting antibodies, expanding the scope of effective treatment to a wider cohort of AML patients. Parallel development pipelines are pursuing BH3 mimetics directed against MCL-1 and BCL-xL, leveraging advances in medicinal chemistry and structural biology to create novel inhibitors with improved selectivity and potency.

Taken together, this landmark review from NUS Medicine not only encapsulates the profound clinical advances ushered in by BH3 mimetics in AML but also delineates critical scientific and therapeutic challenges ahead. Through multi-disciplinary collaboration and continued innovation, researchers are poised to extend the benefits of these promising agents, paving the way for a new era where acute myeloid leukaemia becomes a disease defined not by its lethality but by the hope of durable remission and long-term survival.

Subject of Research: Acute Myeloid Leukaemia treatment using BH3 mimetics
Article Title: Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia
News Publication Date: 1-Sep-2025
Web References: https://www.nature.com/articles/s41571-025-01068-0
References: DOI 10.1038/s41571-025-01068-0
Image Credits: NUS Medicine
Keywords: Leukemia, Cancer, Myeloid leukemia, Oncology, Tumor regression, Tumor growth, Cancer risk, Blood cancer, Cell apoptosis

One of AML’s defining features is a pervasive block in the differentiation of myeloid progenitor cells within the bone marrow. This obstruction arrests the maturation of these cells, resulting in the accumulation of immature precursors that flood the marrow and peripheral blood. This paralyses normal hematopoiesis—the vital process governing the generation and renewal of blood cells—undermining not just immune competence but a multitude of physiological functions reliant on healthy blood cell populations. Recognizing this differentiation blockade as a keystone of AML pathology has long inspired researchers to explore therapeutic avenues that could dismantle this barrier.

Led by Professor Yang Shi of Ludwig Oxford and Dr. Amir Hosseini, with pivotal contributions from Abhinav Dhall at Harvard Medical School, and collaborators at the University of Pennsylvania and University of Helsinki, the study introduces a novel combination drug therapy that tackles AML at this very checkpoint. Their work hinges on a dual mechanism designed to simultaneously activate gene expression programs that promote cellular differentiation while actively repressing those that fuel unchecked proliferation and tumorigenesis. This two-pronged approach is meticulously crafted to coax leukemic cells out of their arrested developmental state and curb their malignant growth kinetics.

Historically, the concept of differentiation therapy in AML is not new. Acute promyelocytic leukemia (APL), a distinct AML subtype, has been effectively treated with differentiation agents such as all-trans retinoic acid combined with arsenic trioxide, achieving cure rates near 95%. However, this success has been largely restricted to APL, leaving a vast majority of AML patients without analogous effective differentiation-based treatments. Addressing this unmet need, Shi and his colleagues have turned their focus to epigenetic regulators—enzymes that modulate gene expression without altering the underlying DNA sequence—specifically targeting key drivers of the differentiation blockade.

Central to the researchers’ strategy is LSD1 (lysine-specific demethylase 1), an enzyme first identified by Shi’s laboratory in 2004. LSD1 functions as an epigenetic eraser, removing methyl groups from histone proteins around which DNA is tightly coiled, thereby influencing the accessibility of genes to the cellular machinery that transcribes them. In AML cells, heightened LSD1 activity contributes to the maintenance of leukemic stem cells by reinforcing the gene expression landscape that enforces their immature, undifferentiated state. While LSD1 inhibitors have shown potential in inducing differentiation, their clinical application has been hampered by high toxicity when administered as monotherapies.

To overcome this, the study employed a systematic screen using mouse leukemic cells to identify drugs that could synergize with LSD1 inhibitors, ultimately spotlighting a clinically evaluated GSK3α/β inhibitor as a potent partner. Glycogen synthase kinase 3 (GSK3) is an enzyme known to participate in a litany of cellular processes, including WNT signaling—a pathway frequently hijacked in cancers including AML, promoting stemness and proliferation. Combining low-dose LSD1 inhibition with GSK3 blockade proved to be a potent formula for inducing differentiation and halting proliferation across multiple AML subtypes in vitro.

Subsequent in vivo experiments provided further encouragement. When administered to mice engrafted with human AML cells, the combination therapy not only promoted leukemic cell maturation and suppressed their division but also extended the survival of these animal models. Intriguingly, the therapeutic effects appeared to selectively target leukemic cells without adversely affecting normal hematopoietic stem cells, suggesting a favorable therapeutic index that could translate into lower toxicity profiles for patients.

The molecular analyses underpinning these findings revealed that the drug combination reprograms gene expression networks by suppressing the stemness signature that confers malignancy, while promoting differentiation pathways. This molecular rewiring mitigates the pathological overactivation of the WNT signaling cascade—an insight that may have far-reaching implications beyond AML, potentially informing treatment strategies for other malignancies marked by similar pathway dysregulations.

Moreover, gene-expression profiling of AML patients demonstrated that the therapeutic signature induced by the drug combo aligns with the expression landscape observed in individuals exhibiting prolonged survival. This correlation underscores the potential real-world relevance of the preclinical findings and bolsters the rationale for advancing this treatment regimen into clinical trials. Both LSD1 and GSK3α/β inhibitors are already under clinical evaluation for other indications, smoothing the pathway for translational research and swift clinical implementation.

The team’s holistic approach blends innovative epigenetic modulation with an existing pharmacological arsenal to surmount a longstanding hurdle in AML therapy. By dismantling the differentiation blockade, their combination therapy holds promise not only for extending survival but also for improving the quality of life in AML patients, who often endure toxic and debilitating treatments. The prospect of converting a lethal, rapidly progressing cancer into a manageable or even curable disease marks a new frontier in oncology.

Looking ahead, the investigators are poised to translate these promising preclinical results into human clinical trials, where safety and efficacy will be rigorously tested. Their work exemplifies the power of integrative science—melding molecular biology, pharmacology, and clinical insight—to produce breakthrough therapies. If successful, this approach could redefine AML treatment standards and inspire analogous strategies against other epigenetically driven cancers.

This landmark study was made possible through generous support from Ludwig Cancer Research, the U.S. National Institutes of Health, the Research Council of Finland, Cancer Foundation Finland, the Sigrid Jusélius Foundation, the National Institute for Health Research, the Oxford Biomedical Research Centre, and Cancer Research UK. Harnessing the synergy of international expertise and funding, it represents a collective stride forward in the global battle against cancer.

In addition to his leadership role at Ludwig Oxford, Yang Shi serves as a Professor in the Nuffield Department of Medicine at the University of Oxford, further underscoring the study’s strong academic foundation. The collaborative, interdisciplinary nature of this research embodies the future of cancer therapeutics, where innovative ideas swiftly transition from bench to bedside, offering renewed hope to patients facing devastating diagnoses.

Subject of Research: Therapeutic strategies targeting differentiation blockade in acute myelogenous leukemia (AML)

Article Title: Not provided

News Publication Date: April 16, 2025

Web References:
https://www.nature.com/articles/s41586-025-08915-1

References: Information not explicitly provided beyond the publication in Nature.

Image Credits: Not provided

Keywords: Health and medicine, Cancer research, Cancer, Genomics